RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of “Hold” by Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $5.29.

Several equities analysts have recently commented on the stock. Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Stifel Nicolaus restated a “hold” rating and set a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Thursday, December 26th. Finally, Wells Fargo & Company lowered their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th.

RAPT Therapeutics Price Performance

Shares of NASDAQ RAPT opened at $1.09 on Friday. The stock has a market capitalization of $38.10 million, a PE ratio of -0.39 and a beta of 0.03. The business has a fifty day moving average price of $1.30 and a two-hundred day moving average price of $1.61. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $10.05.

Institutional Investors Weigh In On RAPT Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of RAPT. Medicxi Ventures Management Jersey Ltd bought a new position in RAPT Therapeutics in the fourth quarter valued at about $35,316,000. TCG Crossover Management LLC bought a new position in RAPT Therapeutics in the 4th quarter valued at approximately $19,751,000. Orbimed Advisors LLC acquired a new stake in RAPT Therapeutics during the 4th quarter worth approximately $20,754,000. Foresite Capital Management VI LLC bought a new stake in RAPT Therapeutics during the 4th quarter worth approximately $19,750,000. Finally, RTW Investments LP acquired a new position in RAPT Therapeutics in the 4th quarter valued at approximately $18,587,000. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.